2022-01-26| Funding

Google-Backed Leyden Labs Closes $140 Million Series B to Fight Viruses with Nasal Spray

by Joy Lin
Share To

Dutch biotech Leyden Labs may have been founded in the early days of the Covid-19 pandemic, but that didn’t stop it from raising $200 million in 2021 to fund the development of treatments against respiratory viruses. The firm recently completed a $140 million Series B financing round led by Series A investors Casdin Capital and GV (formerly known as Google Ventures). 

The fundraising round welcomed new investors such as Softbank Vision Fund 2, Invus, and Bluebird Capital, as well as existing Series A investors F-Prime Capital and Byers Capital/ Brook Byers. 

Additionally, Eli Casdin of Casdin Capital will join Leyden’s board of directors, while Vali Barsen of Softbank Investment Advisers, Jeff Bird of Bluebird Ventures, and Suzanne Jung Angell of Casdin Capital will join the Board as observers. 

The cash injection will go into Leyden’s platform and portfolio development, as well as team expansion.  

Related Article: GeneOnline’s Pick: Notable Novel FDA Approved Drugs in 2021

Anti-Influenza Antibody Licensed from Johnson and Johnson


Leyden’s lead candidate is PanFlu, an intranasal spray that delivers CR9114, a human monoclonal antibody that fights against influenza A and B. CR9114 was licensed from Janssen, a Johnson and Johnson company, last week. Under the deal, Leyden paid Janssen an undisclosed sum, and will also make milestone payments in exchange for a worldwide license to develop and market the drug, which can be administered through the nose and throat. 

Last July, Leyden began a partnership with UK-based company Nanopharm to develop nasal sprays for respiratory viruses.

© All rights reserved. Collaborate with us:
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
Company Presentations at BIO 2024 Inspire Partnering
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
BIO Releases DEI Survey in Partnership with Korn Ferry
Advancing Healthcare Accessibility and Sustainable Development
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
Scroll to Top